vs
Assertio Holdings, Inc.（ASRT）与CUMBERLAND PHARMACEUTICALS INC（CPIX）财务数据对比。点击上方公司名可切换其他公司
CUMBERLAND PHARMACEUTICALS INC的季度营收约是Assertio Holdings, Inc.的1.0倍（$13.7M vs $13.5M），CUMBERLAND PHARMACEUTICALS INC同比增速更快（31.1% vs -57.9%），过去两年CUMBERLAND PHARMACEUTICALS INC的营收复合增速更高（26.9% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
坎伯兰制药是一家专科制药企业，专注于开发、生产和商业化品牌处方药物，核心产品覆盖急症护理、胃肠病、疼痛管理及罕见病治疗领域，主要运营市场为美国，为相关医护人员与患者提供服务。
ASRT vs CPIX — 直观对比
营收规模更大
CPIX
是对方的1.0倍
$13.5M
营收增速更快
CPIX
高出89.0%
-57.9%
两年增速更快
CPIX
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $13.7M |
| 净利润 | — | $-1.4M |
| 毛利率 | — | 83.6% |
| 营业利润率 | -86.7% | -10.0% |
| 净利率 | — | -10.3% |
| 营收同比 | -57.9% | 31.1% |
| 净利润同比 | — | 25.8% |
| 每股收益（稀释后） | $-4.54 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTCPIX
| Q4 25 | $13.5M | $13.7M | ||
| Q3 25 | $49.5M | $8.3M | ||
| Q2 25 | $29.2M | $10.8M | ||
| Q1 25 | $26.5M | $11.7M | ||
| Q4 24 | $32.2M | $10.4M | ||
| Q3 24 | $29.2M | $9.1M | ||
| Q2 24 | $31.1M | $9.8M | ||
| Q1 24 | $32.4M | $8.5M |
净利润ASRTCPIX
| Q4 25 | — | $-1.4M | ||
| Q3 25 | $11.4M | $-1.9M | ||
| Q2 25 | $-16.4M | $-740.7K | ||
| Q1 25 | $-13.5M | $1.3M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-2.9M | $-1.5M | ||
| Q2 24 | $-3.7M | $-1.1M | ||
| Q1 24 | $-4.5M | $-1.9M |
毛利率ASRTCPIX
| Q4 25 | — | 83.6% | ||
| Q3 25 | — | 88.1% | ||
| Q2 25 | — | 81.4% | ||
| Q1 25 | — | 87.8% | ||
| Q4 24 | — | 81.1% | ||
| Q3 24 | — | 85.4% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | — | 81.5% |
营业利润率ASRTCPIX
| Q4 25 | -86.7% | -10.0% | ||
| Q3 25 | 23.2% | -23.7% | ||
| Q2 25 | -27.5% | -6.9% | ||
| Q1 25 | -50.0% | 11.0% | ||
| Q4 24 | -41.9% | -17.7% | ||
| Q3 24 | -10.4% | -18.6% | ||
| Q2 24 | -11.6% | -10.4% | ||
| Q1 24 | -13.4% | -22.0% |
净利率ASRTCPIX
| Q4 25 | — | -10.3% | ||
| Q3 25 | 23.1% | -23.4% | ||
| Q2 25 | -56.0% | -6.8% | ||
| Q1 25 | -51.1% | 10.7% | ||
| Q4 24 | — | -18.2% | ||
| Q3 24 | -10.0% | -17.0% | ||
| Q2 24 | -11.8% | -11.0% | ||
| Q1 24 | -13.9% | -22.9% |
每股收益（稀释后）ASRTCPIX
| Q4 25 | $-4.54 | $-0.09 | ||
| Q3 25 | $0.11 | $-0.13 | ||
| Q2 25 | $-0.17 | $-0.05 | ||
| Q1 25 | $-0.14 | $0.08 | ||
| Q4 24 | $-3.28 | $-0.13 | ||
| Q3 24 | $-0.03 | $-0.11 | ||
| Q2 24 | $-0.04 | $-0.08 | ||
| Q1 24 | $-0.05 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $11.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $24.9M |
| 总资产 | $267.0M | $76.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTCPIX
| Q4 25 | $63.4M | $11.4M | ||
| Q3 25 | $93.4M | $15.2M | ||
| Q2 25 | $98.2M | $16.1M | ||
| Q1 25 | $87.3M | $15.1M | ||
| Q4 24 | $100.1M | $18.0M | ||
| Q3 24 | $88.6M | $17.5M | ||
| Q2 24 | $88.4M | $17.3M | ||
| Q1 24 | $80.7M | $18.5M |
总债务ASRTCPIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTCPIX
| Q4 25 | $94.0M | $24.9M | ||
| Q3 25 | $105.8M | $26.1M | ||
| Q2 25 | $93.3M | $28.0M | ||
| Q1 25 | $108.5M | $28.7M | ||
| Q4 24 | $121.1M | $22.9M | ||
| Q3 24 | $130.5M | $24.8M | ||
| Q2 24 | $132.2M | $26.3M | ||
| Q1 24 | $134.5M | $27.5M |
总资产ASRTCPIX
| Q4 25 | $267.0M | $76.8M | ||
| Q3 25 | $319.8M | $65.9M | ||
| Q2 25 | $273.8M | $67.9M | ||
| Q1 25 | $286.4M | $69.9M | ||
| Q4 24 | $284.7M | $75.6M | ||
| Q3 24 | $276.0M | $76.7M | ||
| Q2 24 | $279.4M | $78.5M | ||
| Q1 24 | $282.0M | $81.5M |
负债/权益比ASRTCPIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $3.0K |
| 自由现金流经营现金流 - 资本支出 | — | $3.0K |
| 自由现金流率自由现金流/营收 | — | 0.0% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $4.8M |
8季度趋势，按日历期对齐
经营现金流ASRTCPIX
| Q4 25 | $-30.0M | $3.0K | ||
| Q3 25 | $-4.8M | $187.2K | ||
| Q2 25 | $19.1M | $843.8K | ||
| Q1 25 | $-12.5M | $3.9M | ||
| Q4 24 | $11.5M | $1.9M | ||
| Q3 24 | $-35.0K | $475.5K | ||
| Q2 24 | $7.4M | $-855.7K | ||
| Q1 24 | $7.5M | $-2.1M |
自由现金流ASRTCPIX
| Q4 25 | — | $3.0K | ||
| Q3 25 | — | $163.4K | ||
| Q2 25 | — | $817.3K | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $460.1K | ||
| Q2 24 | — | $-862.8K | ||
| Q1 24 | — | $-2.2M |
自由现金流率ASRTCPIX
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 32.9% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | -8.8% | ||
| Q1 24 | — | -25.6% |
资本支出强度ASRTCPIX
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.5% |
现金转化率ASRTCPIX
| Q4 25 | — | — | ||
| Q3 25 | -0.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.10× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
CPIX
暂无分部数据
